Download MendeleyIdentification of the Clinical Development CandidateMRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer.
Fell, J.B., Fischer, J.P., Baer, B.R., Blake, J.F., Bouhana, K., Briere, D.M., Brown, K.D., Burgess, L.E., Burns, A.C., Burkard, M.R., Chiang, H., Chicarelli, M.J., Cook, A.W., Gaudino, J.J., Hallin, J., Hanson, L., Hartley, D.P., Hicken, E.J., Hingorani, G.P., Hinklin, R.J., Mejia, M.J., Olson, P., Otten, J.N., Rhodes, S.P., Rodriguez, M.E., Savechenkov, P., Smith, D.J., Sudhakar, N., Sullivan, F.X., Tang, T.P., Vigers, G.P., Wollenberg, L., Christensen, J.G., Marx, M.A.(2020) J Med Chem 63: 6679-6693
- PubMed: 32250617 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.9b02052
- Primary Citation Related Structures:
6USX, 6USZ, 6UT0 - PubMed Abstract:
Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRAS G12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRAS G12C is described.
- Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States.
Organizational Affiliation:
